GFH312

DRUG2 trials

Sponsors

GenFleet Therapeutics (Australia) Pty Ltd., Zhejiang Genfleet Therapeutics Co., Ltd.

Conditions

HealthyIntermittent ClaudicationPeripheral Artery DiseaseToxicity

Phase 1

A Study of GFH312 in Healthy Subjects

CompletedNCT04676711

GenFleet Therapeutics (Australia) Pty Ltd.Healthy, Toxicity

Start: 2021-04-27End: 2022-10-31Updated: 2023-05-15

Phase 2

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

WithdrawnNCT05618691

Zhejiang Genfleet Therapeutics Co., Ltd.Intermittent Claudication, Peripheral Artery Disease

Start: 2022-12-01End: 2024-05-31Updated: 2023-09-06